Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26466014 | 0.89 | ALDH1A1 (0.35) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL26466005 | 0.83 | ALDH1A1 (0.30) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL26099388 | 0.76 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL26097750 | 0.67 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL6926870 | 0.64 | NPC1 (0.37) | ALDH1A1TP53TSHRSMN1; SMN2 | |
| SCHEMBL6512199 | 0.62 | L3MBTL1 (0.59) | APPIDO1AGXT | |
| SCHEMBL4728877 | 0.61 | L3MBTL1 (0.62) | SMN1; SMN2APPIDO1AGXT | |
| SCHEMBL16727734 | 0.60 | L3MBTL1 (0.65) | SMN1; SMN2APPIDO1AGXT | |
| SCHEMBL1355360 | 0.60 | L3MBTL1 (0.65) | SMN1; SMN2APPIDO1AGXT | |
| SCHEMBL27089918 | 0.60 | L3MBTL1 (0.65) | SMN1; SMN2APPIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ALDH1A1 383/4885TP53 4159/4885CYP3A4 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.